HomeProductsBuilding BlocksHeterocyclic ScaffoldsQuinoxalinesTalviraline
Chemical structure of CAS 163451-80-7

Talviraline

In Stock•Starting at $166 for 1 mg
CAS No.163451-80-7
MDL No.N/A
MFC15H20N2O3S2
MW340.50
InChI KeyGWKIPRVERALPRD-ZDUSSCGKSA-N
CUSTOM SYNTHESIS

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mgTo Be Confirmed$166In Stock
5 mgTo Be Confirmed$408In Stock
10 mgTo Be Confirmed$612In Stock
25 mgTo Be Confirmed$996In Stock
50 mgTo Be Confirmed$1400In Stock
100 mgTo Be Confirmed$1801In Stock
500 mgTo Be Confirmed$3612In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.163451-80-7
Product NameTalviraline
Heavy Atom Count22Rotatable Bond Count4
Atom Stereo Count1Bond Stereo Count0
HBA5HBD1
TPSA50.800 ŲCharge0
Exact Mass340.09153Complexity577.91
pKa5.875XLogP3.531

Related Articles

Studies related to this compound and its mechanism of action

Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.

Molecular pharmacology • Vol. 57, Issue 5 • 2000
PMID: 10779379

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.

Journal of medicinal chemistry • Vol. 42, Issue 20 • 1999
PMID: 10514285DOI: 10.1021/jm990095j

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

AIDS research and human retroviruses • Vol. 14, Issue 3 • 1998
PMID: 9491916DOI: 10.1089/aid.1998.14.255

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).

Biochemical pharmacology • Vol. 55, Issue 5 • 1998
PMID: 9515572DOI: 10.1016/s0006-2952(97)00506-6

Documentation